Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Primary IgA Nephropathy (Phase II, China)
CTR20260121Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2026
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2173 in IgA nephropathy (IgAN), sponsored by Hengrui Therapeutics. Started Apr 2026; status: active.
02
Drugs
SHR-2173
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20260121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260121.